Clinical Commander

All dossiers
cardio.atrial_flutter.endurance-athlete.v1

Atrial flutter in the long-term endurance athlete

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E variant of cardio.atrial_flutter.v1 — endurance-athlete AFL. Substrate: chronic high-volume endurance (marathon, cycling, cross-country skiing, triathlon, long-course swimming ≥10 cumulative years) → LA dilation + vagal bradycardia + atrial fibrosis → AFL/AF risk 2-5× sedentary. Demographics: middle-aged males predominant. Acute: cautious BB short-acting (esmolol preferred; metoprolol low-dose) given baseline resting HR 40-55; diltiazem alternative; AVOID amiodarone first-line in young athlete (long-term toxicity prohibitive over decades); low DCCV threshold for symptomatic patients planning return-to-training. Definitive: EARLY CTI ablation for typical AFL (>95% success per HRS/EHRA/ECAS 2017 PMID 28506916). Long-term anchor: TRAINING VOLUME REDUCTION (dose-responsive substrate reversal per Andersen 2013 PMID 23736857, Mont 2002 PMID 12099811, Mohanty 2016 PMID 27340861) — single most powerful intervention. Comorbid axes: OSA treatment reduces recurrence 30-50%; alcohol cessation (Voskoboinik 2020 PMID 31893513). AC strategy: 4-wk post-CV mandatory; long-term per CHA2DS2-VASc (often 0-1) with sport-trauma bleed weighting; DOAC preferred over warfarin (active lifestyle, no INR monitoring, no diet interference); LAAO consideration if recurrent bleed + AC contraindication. Severity triggers: tachycardia-mediated CMP (recovers with rate control + ablation); WPW with rapid AFL conduction (AVOID AV nodal blockers, procainamide preferred); syncope in athlete (broad SCD evaluation per Maron PMID 26621650); ablation failure or recurrence (re-ablation typically successful); major bleed (LAAO consideration). Sibling differentiation: routes typical CTI ablation pathway to cardio.atrial_flutter.typical-cavotricuspid.v1; cross-links to cardio.afib.core.v1 (30-50% co-occurrence); coexists with cardio.atrial_flutter.alcohol-related.v1 when athlete also drinks heavily; routes tachycardia-mediated CMP to cardio.acute-hf.core.v1. Manifest pointer reuses cardio.atrial_flutter.v1 manifest. Design-brief pointer reuses parent. Status INTEGRATED. Authored 2026-05-15 by shard-06-cardio-acute (Wave 20 recovery batch).

Entry points (4)

  • symptom
    New palpitations, exertional intolerance, or unexpected drop in training power output in long-term endurance athlete (≥10 yr cumulative high-volume training) — AFL/AF likely
    palpitations_or_exertional_intolerance_in_endurance_athlete
  • imaging
    12-lead ECG with atrial flutter pattern + echo showing LA dilation + LV mass increase + low resting HR (athlete's-heart substrate)
    aflutter_on_ecg_in_athlete_with_la_dilation_on_echo
  • history
    Marathon / cycling / triathlon / cross-country skiing background ≥10 y + new-onset AFL/AF; often presents during taper or after very long event
    chronic_endurance_training_with_new_arrhythmia
  • symptom
    Syncope or near-syncope during endurance session — AFL with rapid AV conduction, or rate-related ischemia in young athlete; full arrhythmia + ischemic workup mandatory
    syncope_or_near_syncope_during_training

Required inputs (16)

  • agerequired
    demographic • used at CONTEXT
    Risk concentrated in 40-65 y middle-aged males with cumulative endurance years; pediatric / adolescent cases rare and route to peds-specific dossier
  • sexrequired
    demographic • used at CONTEXT
    Strong male predominance (M:F ≈ 5:1) in endurance-induced AFL/AF; female sex = +1 CHA2DS2-VASc; informs AC threshold + ablation candidacy
  • cumulative_endurance_training_hours_per_week_and_yearsrequired
    history • used at CONTEXT
    Dose-response: >5-10 h/wk for >10 y carries 2-5× AFL/AF risk; quantifies substrate severity; targets training-volume reduction as primary lifestyle Rx (Andersen 2013 PMID 23736857; Mont 2002 PMID 12099811)
  • resting_hr_when_in_sinusrequired
    vital • used at CONTEXT
    Athlete's resting HR commonly 40-55 in NSR; BB titration must be cautious + short-acting; informs CCB vs BB choice for rate control
  • sbprequired
    vital • used at RED_FLAGS
    SBP <90 with flutter RVR = DCCV; athletes often have low-normal baseline SBP (90-110); informs vasoactive thresholds
  • hr_during_aflutterrequired
    vital • used at CONTEXT
    Flutter rate; rate-control target 80-110 (lenient) vs <80 (strict) per RACE-II; very high rates (>180) suggest accessory bypass tract — re-screen WPW
  • ecg_12_leadrequired
    imaging • used at INITIAL_WORKUP
    Confirms flutter morphology (typical CTI-dependent counterclockwise sawtooth in II/III/aVF — most common — vs atypical LA flutter); QT for medication safety; ischemic ST changes
  • transthoracic_echo_with_chamber_quantificationrequired
    imaging • used at INITIAL_WORKUP
    LA volume index (athlete vs pathologic dilation cutoff LAVI >34-40 mL/m²); LV mass index; RV strain; valvular; rule out HCM/ARVC masquerade; bicuspid aortic valve screen (sport-related sudden death cohort)
  • cardiac_mri_with_lge_if_dilation_or_concerning_features
    imaging • used at BRANCHING_WORKUP
    Distinguishes athlete's heart (no LGE, regression on deconditioning) from pathologic CMP (HCM, ARVC, sarcoid, prior myocarditis); also assesses LA scar burden which predicts ablation success
  • tsh_to_exclude_thyrotoxicosis_overlayrequired
    lab • used at CONTEXT
    Excludes thyrotoxicosis-precipitated AFL (would route to cardio.atrial_flutter.thyroid-related.v1); athletes occasionally on supraphysiologic T4 for performance
  • cbc_chem_panel_creatininerequired
    lab • used at INITIAL_WORKUP
    eGFR for DOAC dosing; CBC for anemia (athletes occasionally over-trained anemia); BUN/Cr; Mg + K (training-induced electrolyte shifts can drive arrhythmia)
  • troponinrequired
    lab • used at INITIAL_WORKUP
    Rule out demand ischemia at high flutter rates; small troponin rise common post-marathon but persistent + clinical concern → ACS evaluation
  • cha2ds2_vasc_factorsrequired
    history • used at RISK_STRATIFICATION
    Often 0-1 in this cohort (young male, no DM/HTN/HF) — AC threshold + duration decisions; thresholds in young male athletes weigh trauma + lifestyle vs stroke
  • bleeding_or_trauma_historyrequired
    history • used at RISK_STRATIFICATION
    HAS-BLED + active sport increases trauma-related bleed risk on AC; informs DOAC vs no AC after CV; LAAO discussion in selected
  • osa_sleep_apnea_screenrequired
    history • used at BRANCHING_WORKUP
    High prevalence in middle-aged endurance males via increased neck circumference + supine training adaptations; treating OSA reduces AFL/AF recurrence by 30-50% (CAPPS PMID 27744102)
  • alcohol_intake_and_recreational_drugsrequired
    history • used at CONTEXT
    Endurance cohort often has higher alcohol prevalence; cross-link to cardio.atrial_flutter.alcohol-related.v1 if heavy; stimulant supplements (caffeine, ephedrine-class pre-workouts, anabolic steroids) can precipitate

12-phase flow (11)

  1. 1FRAME
    Endurance-athlete AFL: chronic high-volume training → LA dilation + vagal bradycardia + atrial fibrosis → AFL substrate. Acute: cautious rate control (BB short-acting low-dose given baseline bradycardia; diltiazem if BB intolerance), low DCCV threshold for symptomatic athletes, AC per CHA2DS2-VASc with sport-trauma considerations. Long-term: training-VOLUME REDUCTION is anchor intervention; early CTI ablation for typical AFL (>95% success per HRS/EHRA/ECAS 2017); OSA + alcohol screen + treatment
    inputs: ecg_12_lead, tsh_to_exclude_thyrotoxicosis_overlay
    advance: endurance-athlete AFL phenotype framed
  2. 2ENTRY
    Quantify symptoms (palpitations, exertional intolerance, drop in power output, syncope); 12-lead ECG; rapid bedside echo for chamber size; SCAI shock screen; ETT post-stabilization for ischemic + rate-response screen
    inputs: age, sex, hr_during_aflutter, resting_hr_when_in_sinus
    advance: AFL confirmed + acuity + structural substrate documented
  3. 3CONTEXT
    Training history (sport, weekly hours, cumulative years, ramp-up patterns), OSA screen (STOP-BANG / NoSAS), alcohol + supplement + performance-enhancing drug history, family history (sudden death, HCM, ARVC, channelopathies)
    inputs: cumulative_endurance_training_hours_per_week_and_years, osa_sleep_apnea_screen, alcohol_intake_and_recreational_drugs, cbc_chem_panel_creatinine
    advance: substrate + comorbid drivers documented
  4. 4RED_FLAGS
    Hemodynamically unstable flutter (SBP <90, syncope, severe angina) → DCCV; WPW-like rates >250 → unique pathway with avoidance of AV nodal blockers; troponin elevation → demand ischemia or concomitant ACS workup; new severe LV dysfunction → tachycardia-mediated cardiomyopathy
    inputs: sbp, troponin
    actions: acs_pathway
    advance: red flags screened
  5. 5INITIAL_WORKUP
    12-lead ECG (morphology), TTE (LA volume index, LV mass, valvular, rule out HCM/ARVC), CMP + Mg + TSH + troponin + CBC; telemetry; pregnancy test reproductive-age females
    inputs: ecg_12_lead, transthoracic_echo_with_chamber_quantification, troponin
    actions: panel.cardiac, panel.renal
    advance: workup documents AFL + substrate + ischemic exclusion
  6. 6BRANCHING_WORKUP
    Cardiac MRI if echo suggests pathologic dilation (HCM, ARVC, sarcoid, prior myocarditis); 14-30d Holter for AF burden + concomitant atrial arrhythmias; sleep study for OSA; ETT for rate response + ischemic screen; family screening for SCD risk if concerning history
    inputs: cardiac_mri_with_lge_if_dilation_or_concerning_features
    actions: afib_new_onset, tachycardia
    advance: substrate + masquerades + comorbid drivers fully characterized
  7. 7RISK_STRATIFICATION
    CHA2DS2-VASc (often 0-1) for AC indication; HAS-BLED for bleed risk; weigh sport-related trauma risk for AC duration; eGFR for DOAC dose; ablation candidacy assessment per substrate
    inputs: cha2ds2_vasc_factors, bleeding_or_trauma_history
    actions: calc.cha2ds2vasc, calc.has_bled, calc.ckd_epi_2021
    advance: AC + ablation + return-to-sport plan documented
  8. 8TREATMENT
    Acute: cautious BB short-acting (esmolol IV 25-100 µg/kg/min titrate to HR 80-110; metoprolol tartrate 12.5-25 mg PO low-dose) given baseline bradycardia; diltiazem 0.25 mg/kg IV bolus + 5-15 mg/h infusion as BB alternative; AVOID amiodarone first-line in young athlete (long-term pulm/thyroid toxicity); DCCV 50-100 J biphasic synchronized low threshold for symptomatic; apixaban 5 mg BID for ≥4 wk post-CV; long-term per CHA2DS2-VASc. Definitive: early CTI ablation for typical AFL (>95% success HRS/EHRA/ECAS 2017 PMID 28506916). Lifestyle: training volume reduction (cut to <5 h/wk submaximal for 3-6 mo trial), OSA treatment if positive, alcohol cessation
    inputs: resting_hr_when_in_sinus
    advance: rate/rhythm control + AC + ablation pathway + lifestyle plan initiated
  9. 9DISPOSITION
    Outpatient management feasible if stable rate-controlled flutter + asymptomatic at rest + AC initiated + EP follow-up booked; admit telemetry if hemodynamic concern, new severe LV dysfunction, WPW pattern, or syncope unexplained; ICU rare unless tachycardia-mediated CMP with shock
    advance: disposition documented
  10. 10MONITORING
    24-48 h telemetry if admitted; ambulatory rhythm monitor (Holter 14-30 d or smartwatch) for AF burden; surveillance echo at 3 + 6 mo for chamber regression with detraining; INR weekly if warfarin; eGFR q6mo on DOAC
    inputs: ecg_12_lead
    advance: monitoring active + ablation timeline documented
  11. 11FOLLOWUP
    EP referral for early CTI ablation candidacy (typical AFL >95% acute success); cardiology q3 mo first year then q6-12 mo; sleep medicine if OSA positive; sport-medicine + cardiac rehab gradual return-to-training plan; AC reassessment annually per CHA2DS2-VASc; cardiac MRI surveillance if pathologic dilation suspected; consider LAAO if ablation refractory + AC contraindicated
    advance: long-term EP + sport + AC + comorbid plan documented